Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Weight loss of at least 5% was observed in 63.2 and 27.1% of the patients, respectively, and weight loss 10% was seen in 33.1 and 10.6% of the patients, respectively
Patients may initiate sexual activity at varying time points relative to dosing in order to determine their own optimal window of responsiveness
Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, OFarrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
categorical variables are expressed as numbers and percentages
